Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- YUMC +8.5%, CC +8.3%, GTE +6.2%, FRPT +4%, ZTS +3.1%, BNTX +2.4%, KNF +1.6%, IART +1.1%, FIS +1%
Other news:
- DERM +12.5% (FDA has approved Emrosi, formerly referred to as DFD-29, for the treatment of inflammatory lesions of rosacea in adults)
- VKTX +9.7% (reports new data from VK2735 obesity program at ObesityWeek 2024)
- GTE +6.2% (announces normal course issuer bid and automatic share purchase plan)
- CANF +5.6% (announced an update related to the intellectual property (IP) status of its lead drug candidate Namodenoson)
- CHWY +4.9% (to join S&P MidCap 400)
- KZIA +4.2% (to delay 20-F filing)
- TYRA +4% (CFO bought 9500 shares at $15.9952 worth ~$152K)
- SKYE +3.8% (announces preliminary data from a diet-induced obesity model in mice)
- CRBP +3.7% (presents new CRB-913 pre-clinical data at Obesity Week 2024)
- SHW +3.4% (will replace DOW in DJIA)
- BORR +2.7% (announces voluntary delisting from Oslo Stock Exchange)
- OKUR +2.5% (to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium)
- NVDA +2.2% (will replace INTC in DJIA)
- MNKD +2% (successfully completes phase 1 trial of Nintedanib DPI for pulmonary fibrotic diseases)
- QGEN +1.7% (receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel)
- E +1.6% (completes sale of upstream assets in Alaska to Hilcorp)
- SVM +1.5% (files mineral resource technical report of Baiyunpu Gold-Lead-Zinc Project)
- ELS +1.4% (files for $700 mln common stock offering)
- GUTS +1.4% (presented new analysis from pooled data of Revita clinical studies demonstrating durable weight loss maintenance for one year at ObesityWeek 2024)
- LIVN +1% (CMS maintaining VNS Therapy for drug-resistant epilepsy at the Level 5 Neurostimulator and Related Procedures APC)